{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Table 13', '95% confidence intervals of AECOPD incidence rates with different', 'overdispersion values', 'Q 1', 'Q = 1.5', '$ =2', '0.2.EECOPD/subject/year', '95% CI*', '95% CI*', '95% CI*', 'T', 'n', 'Value (n/T)', 'LL', 'UL', 'LL', 'UL', 'LL', 'UL', '30', '6', '0.20', '0.04', '0.36', '0.00', '0.40', '-0.03', '0.43', '100', '20', '0.20', '0.11', '0.29', '0.09', '0.31', '0.08', '0.32', '130', '26', '0.20', '0.12', '0.28', '0.11', '0.29', '0.09', '0.31', '150', '30', '0.20', '0.13', '0.27', '0.11', '0.29', '0.10', '0.30', '1 AECOPD/ /subject/year', '95% CI*', '95% CI*', '95% CI*', 'T', 'n', 'Value (n/T)', 'LL', 'UL', 'LL', 'UL', 'LL', 'UL', '40', '40', '1.00', '0.69', '1.31', '0.62', '1.38', '0.56', '1.44', '130', '130', '1.00', '0.83', '1.17', '0.79', '1.21', '0.76', '1.24', '160', '160', '1.00', '0.85', '1.15', '0.81', '1.19', '0.78', '1.22', '190', '190', '1.00', '0.86', '1.14', '0.83', '1.17', '0.80', '1.20', '2 AECOPD/subject/year', '95% CI*', '95% CI*', '95% CI*', 'T', 'n', 'Value (n/T)', 'LL', 'UL', 'LL', 'UL', 'LL', 'UL', '40', '80', '2.00', '1.56', '2.44', '1.46', '2.54', '1.38', '2.62', '130', '260', '2.00', '1.76', '2.24', '1.70', '2.30', '1.66', '2.34', '160', '320', '2.00', '1.78', '2.22', '1.73', '2.27', '1.69', '2.31', '190', '380', '2.00', '1.80', '2.20', '1.75', '2.25', '1.72', '2.28', '3 AECOPD/subject/yeal', '95% CI*', '95% CI*', '95% CI*', 'T', 'n', 'Value (n/T)', 'LL', 'UL', 'LL', 'UL', 'LL', 'UL', '40', '120', '3.00', '2.46', '3.54', '2.34', '3.66', '2.24', '3.76', '130', '390', '3.00', '2.70', '3.30', '2.64', '3.36', '2.58', '3.42', '160', '480', '3.00', '2.73', '3.27', '2.67', '3.33', '2.62', '3.38', '190', '570', '3.00', '2.75', '3.25', '2.70', '3.30', '2.65', '3.35', '* Normal approximation with variance = Q n/T2, where Q is the overdispersion factor for a Poisson distribution', '(calculations performed in Microsoft Excel).', 'T = Total number of evaluable subjects; n =Total number of exacerbations; CI = confidence interval; LL = lower limit;', 'UL = upper limit.', '9.3.', 'Cohorts for Analyses', 'The following study cohorts will be evaluated.', '9.3.1.', 'All screened Set', 'The all screened set will include all screened patients.', '9.3.2.', 'All Enrolled Set', 'The all enrolled set will include all successfully screened subjects in the study.', '19-OCT-2018', '68', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '9.3.3.', 'Full Analysis Set', 'The Full Analysis Set (FAS) will include all enrolled patients except for those who', 'discontinued the study during Visit 1.', 'Study objectives will be assessed on the FAS. The population set for each analysis will', 'change according to the subjects evaluable for the specific endpoint.', 'Note: Subjects using antibiotics on a continual basis (defined as more than 1 month in', 'total) will be allowed to continue study participation, but may be eliminated from the', 'analyses.', '9.4.', 'Analysis of demographics', 'Demographic characteristics (age at enrolment, gender and geographical ancestry) and', 'cohort description will be summarised using descriptive statistics:', 'Frequency tables will be generated for categorical variable such as geographical', 'ancestry.', 'Mean, median, standard deviation, minimum and maximum will be provided for', 'continuous data such as age.', 'The distribution of subjects enrolled among the study sites will be tabulated.', 'Withdrawal status will be summarised according to the reason for withdrawal. The', 'number of withdrawn patients will be tabulated by study visit and overall.', 'All tables will also be generated by country.', '9.5.', 'Analysis of primary objective', 'The proportion of sputum samples obtained at each visit (confirmed stable visits* and', 'AECOPD visits and positive for specific bacterial/ viral pathogens by bacteriological', 'methods and PCR, respectively (overall and by bacterial/viral species) will be computed', 'with 95% confidence intervals.', 'A confirmed stable visit will be defined as a scheduled study visit for which the', 'investigator confirms in the eCRF that the subject is stable/ has recovered from a', 'previous exacerbation.', '19-OCT-2018', '69', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}